Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, a French pharmaceutical group, has announced that it is the first international vaccine company to enter the Japanese pediatric vaccine market with ActHIB vaccine.
Subscribe to our email newsletter
Sanofi Pasteur’s ActHIB vaccine (Haemophilus influenzae type b conjugate vaccine) is marketed in Japan by Daiichi-Sankyo Co and will be available starting December 19, 2008.
Wayne Pisano, president and CEO of Sanofi Pasteur, said: “Sanofi Pasteur is proud to help protect Japanese children against bacterial meningitis and improve public health in the country. Being the first to enter the Japanese pediatric vaccine market is an achievement that underlines Sanofi Pasteur’s strength and commitment to provide the highest quality innovative vaccines.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.